PTC Therapeutics (NASDAQ: PTCT) announced that its oncology program targeting BMI1, a protein linked to drug-resistant cancers, has entered a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE